Cancer Institute

  • Gene L. Bidwell III

    bidwell_gene.jpgAssistant Professor
    Molecular Cancer Therapeutics
    PhD., Biochemistry, 2007, University of Mississippi Medical Center, Jackson, MS
    Postdoctoral Fellowship, 2007-10, University of Mississippi Medical Center, Jackson, MS

    Contact information
    Department of Neurology
    2500 N State St., Room N321-2
    Jackson, MS 39216
    Phone: (601) 984-6787

    Research interests

    • Targeted drug delivery
    • Therapeutic peptides
    • Breast cancer, glioblastoma, pregnancy

    Research synopsis

    My research interests include targeted drug delivery, therapeutic peptides, and protein-based therapeutics.  My background and training included the development of stimulus-responsive drug carriers for targeting drugs to solid tumors.  We utilized a thermally responsive carrier to target therapeutic peptides and small molecule chemotherapeutics to tumor sites using focused heating.  My current research interests include engineering protein carriers for delivery of peptide and protein-based therapeutics in several disease models.

    One of our current areas of focus is drug delivery during pregnancy.  We are developing carriers that can be fused to therapeutic agents, including chemotherapeutics, peptides, and proteins, that prevent them from crossing the placenta and reaching the baby.  Our goal is to develop a means to treat disorders of pregnancy (such as preeclampsia), or to deliver drugs currently unsafe for use during pregnancy, to pregnant patients without risking harm to the developing fetus from drug exposure.

    A second area of interest in my lab is delivery of neurotrophic growth factors to the brain (via intranasal administration or direct focal injection) for therapy of neurological disorders.  We are currently evaluating the delivery of protein carrier-fused growth factors for therapy of neurodegenerative disorders.  Fusion of growth factors as a chimera with this protein carrier allows us to easily purify the agents after recombinant expression and stabilizes them for use in vivo.

    Our lab also has an interest in therapeutic angiogenesis for kidney disease.  We are examining the use of carrier-fused, kidney-targeted growth factors for protection or regeneration of renal vasculature in the context of renal artery stenosis and chronic kidney disease.

    Another area of focus in our lab is developing a drug delivery system for administering therapeutics to the eye.  We are working to create anti-angiogenic and anti-microbial agents that have corneal penetrating capability to treat ocular disorders such as corneal neovascularization and bacterial keratitis.

    Recent accomplishments and honors

    • 2011 - Department of Defense Breast Cancer Research Program Era of Hope Conference Distinguished Postdoctoral Poster Award
    • 2010 - American Association for Cancer Research - Sanofi-Aventis Scholar-in-training Award
    • 2009 - University of Mississippi Medical Center Excellence in Research Award - Bronze Medal

    Selected publications

    • Bidwell, G. L. 3rd, Perkins, E., Hughes, J. D., Khan, M., James, J. R.,and Raucher, D.  Thermally Targeted Delivery of a c-Myc Inhibitory Polypeptide Inhibits Tumor Progression and Extends Survival in a Rat Glioma Model.  PLoS One, 8(1), 2013.  PubMed link Full text open access link      
    •  George, E. M. and Bidwell, G. L. 3rd. STOX1: A new player in preeclampsia?  Hypertension, 61(3): 561-3.  2013.  PubMed link 
    • Bidwell, G. L. 3rd.  Peptides for Cancer Therapy – A Drug Development Opportunity and a Drug Delivery Challenge.  Therapeutic Delivery.  3(5): 609-21.  2012.  PubMed link 
    • Bidwell, G. L. 3rd, Perkins, E.,and Raucher, D.  A thermally targeted c-Myc inhibitory polypeptide inhibits breast tumor growth.  Cancer Letters. 28;319(2):136-43, 2012.  PubMed linkfull text
    • Bidwell, G. L. 3rd and Raucher, D.  Cell penetrating elastin-like polypeptides for therapeutic peptide delivery.  Advanced Drug Delivery Reviews.  30;62(15):1486-96, 2010.  PubMed link. Full text in PMC
    • Bidwell, G. L. 3rd and Raucher, D.  Therapeutic Peptides for Cancer Therapy:  Part I – Peptide Inhibitors of Signal Transduction Cascades.  Expert Opinion on Drug Delivery. 6(10):1033-47, 2009.  PubMed link 
    • Raucher, D., Moktan, S., Massodi, I., and Bidwell, G. L. 3rd.  Therapeutic Peptides for Cancer Therapy:  Part II – Cell Cycle Inhibitory Peptides and Apoptosis Inducing Peptides.  Expert Opinion on Drug Delivery.  6(10):1049-64, 2009.  PubMed link 
    • Bidwell, G. L. 3rd,Davis, A.N., and Raucher, D.  Targeting a c-Myc Inhibitory Polypeptide to Specific Intracellular Compartments using Cell Penetrating Peptides.  J. Control. Release.  135(1):2-10, 2009.  PubMed link. Full text link   
    • Bidwell, G. L. 3rd,Fokt, I., Priebe, W., and Raucher, D. Development of Elastin-like polypeptide for thermally-targeted delivery of doxorubicin. Biochem. Pharmacol. 73(5):620-31, 2007.  PubMed link.
    • Bidwell, G. L. 3rd and Raucher, D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol. Cancer Ther, 4: 1076-1085, 2005.  PubMed link. Full text